Complement levels (C3 and C4) were within normal range, and the absence of diarrhea made typical hemolytic uremic syndrome (HUS) less likely. Given the recent initiation of carfilzomib and the absence of alternative causes, a diagnosis of severe carfilzomib-associated TMA was made. Here, C3 is linked to hemolytic-uremic syndrome.